ARDS - Aridis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3-53.41%
S&P500 52-Week Change 38.78%
52 Week High 313.00
52 Week Low 35.37
50-Day Moving Average 37.63
200-Day Moving Average 39.04

Share Statistics

Avg Vol (3 month) 310.36k
Avg Vol (10 day) 32.23k
Shares Outstanding 58.91M
Float 5.59M
% Held by Insiders 145.04%
% Held by Institutions 10.26%
Shares Short (Sep 30, 2019) 44.81k
Short Ratio (Sep 30, 2019) 40.25
Short % of Float (Sep 30, 2019) 40.08%
Short % of Shares Outstanding (Sep 30, 2019) 40.05%
Shares Short (prior month Aug 30, 2019) 49.63k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-820.96%

Management Effectiveness

Return on Assets (ttm)-110.26%
Return on Equity (ttm)-272.20%

Income Statement

Revenue (ttm)3.44M
Revenue Per Share (ttm)0.48
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-20.24M
EBITDA -27.88M
Net Income Avi to Common (ttm)-29.8M
Diluted EPS (ttm)-4.19
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)8.52M
Total Cash Per Share (mrq)0.96
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)2.66
Book Value Per Share (mrq)1.34

Cash Flow Statement

Operating Cash Flow (ttm)-29.26M
Levered Free Cash Flow (ttm)-19.23M